2011
DOI: 10.1007/s00415-011-6028-7
|View full text |Cite
|
Sign up to set email alerts
|

Cost-of-illness in multiple system atrophy and progressive supranuclear palsy

Abstract: Multiple system atrophy and progressive supranuclear palsy are disabling neurodegenerative disorders, also known as atypical parkinsonian syndromes. Currently, no health economic evaluations of these diseases are available. The objective of this study was to evaluate disease-related costs in German patients with multiple system atrophy and progressive supranuclear palsy and to identify cost-driving factors. We recruited 101 consecutive patients with multiple system atrophy (n = 54) and progressive supranuclear… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

1
1
0

Year Published

2012
2012
2023
2023

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(2 citation statements)
references
References 32 publications
1
1
0
Order By: Relevance
“…Data on the direct medical costs of PSP are scarce. Our findings are in line with two previous publications assessing the economic burden of PSP, demonstrating that disease severity is a significant contributor to the increase of direct costs [8,20]; the semiannual costs increased from €9290 in patients in early stages (1-2, measured by the Unified MSA Rating Scale, Part IV) to €20,630 in patients in advanced stages (4-5) [20]. Similar trends are shown in France, Germany and the UK where disease severity was measured using Parkinson Plus Symptoms scale [8].…”
Section: Discussionsupporting
confidence: 93%
“…Data on the direct medical costs of PSP are scarce. Our findings are in line with two previous publications assessing the economic burden of PSP, demonstrating that disease severity is a significant contributor to the increase of direct costs [8,20]; the semiannual costs increased from €9290 in patients in early stages (1-2, measured by the Unified MSA Rating Scale, Part IV) to €20,630 in patients in advanced stages (4-5) [20]. Similar trends are shown in France, Germany and the UK where disease severity was measured using Parkinson Plus Symptoms scale [8].…”
Section: Discussionsupporting
confidence: 93%
“…[ 3 , 4 ] As the disease progresses, it can decrease the functions of the brain, cardiovascular system, respiratory system, urinary system, etc, [ 5 ] reducing the quality of life and increasing the burden on family and society. [ 6 , 7 ] The pathogenesis underlying MSA remains not fully understood. A loss-of-function mutation in the COQ2 gene encoding by coenzyme Q 10 synthase is the only certified cause of monogenic MSA till now.…”
Section: Introductionmentioning
confidence: 99%